Welcome to our dedicated page for West Pharm Svcs SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the flow of biologic-ready elastomer stoppers through West Pharmaceutical Services鈥� global plants can mean wading through hundreds of technical pages. Every 10-K and 10-Q dissects proprietary component revenue, capital outlays for clean-room expansions, and inspection findings in dense legal language. If you have ever searched 鈥淲est Pharmaceutical Services SEC filings explained simply,鈥� you are not alone. Stock Titan鈥檚 AI-powered summaries translate those disclosures into clear briefs, spotlighting where injectable-device demand, raw-material costs, and supply-chain risks actually move the numbers.
Need fresh data before the market reacts? Our platform streams West Pharmaceutical Services quarterly earnings report 10-Q filing alerts the moment they hit EDGAR, along with real-time West Pharmaceutical Services Form 4 insider transactions. One click reveals segment margins, R&D on wearable auto-injectors, and pension impacts. For governance questions such as 鈥淲est Pharmaceutical Services proxy statement executive compensation,鈥� side-by-side charts show how leadership pay ties to total shareholder return, while our natural-language engine highlights any red flags.
From West Pharmaceutical Services annual report 10-K simplified to West Pharmaceutical Services 8-K material events explained, we cover every disclosure so you can:
- Monitor West Pharmaceutical Services insider trading Form 4 transactions before material events
- Compare contract-manufacturing growth across fiscal years
- Flag supply-agreement announcements in 8-K filings
Whether you鈥檙e reviewing West Pharmaceutical Services earnings report filing analysis or tracking West Pharmaceutical Services executive stock transactions Form 4, Stock Titan delivers expert insight, real-time updates, and searchable archives鈥攇iving you clarity without the clutter.
West Pharmaceutical Services, Inc. files this Form S-8 to register additional employee benefit plan securities and incorporates by reference prior SEC filings, including its Annual Report for the fiscal year ended December 31, 2024 and Quarterly Reports for the quarters ended March 31, 2025 and June 30, 2025. The filing also incorporates Current Reports filed on March 11, 2025; April 14, 2025; April 24, 2025; May 8, 2025 (amended May 12, 2025); and July 21, 2025, plus the description of Common Stock included in Exhibit 4.4 to the 2024 filing.
The company discloses that Ryan Metz, Associate General Counsel, rendered the legal opinion and beneficially owns or has rights to acquire less than 1% of the common stock and is eligible to participate in the 2016 Plan. Article IV of the Bylaws provides indemnification for directors, officers, employees and agents subject to statutory limits, and such indemnification constitutes a contract that cannot be detrimentally amended as to prior acts.
Robert W. McMahon, the company's SVP & Chief Financial Officer, reported an initial beneficial ownership position in West Pharmaceutical Services (WST). He directly holds restricted stock units of 3,168 and 12,670 shares, and two stock options covering 7,647 and 7,137 shares with an exercise price of $240.33. The options become exercisable on 08/11/2026 and expire on 08/11/2035. In total the reported awards underlie 30,622 common shares and are reported as direct beneficial ownership.
Robert W. McMahon, SVP & Chief Financial Officer of West Pharmaceutical Services, Inc. (WST) received equity awards reported for transactions dated 08/11/2025. The awards include 15,838 restricted stock units (RSUs) granted at a $0 price and 14,784 stock options with a $240.33 exercise price. The options become exercisable beginning 08/11/2026 and expire 08/11/2035. The first RSU award vests in three installments (4,223; 6,335; 2,112), and the second vests in four equal annual installments beginning 08/11/2026. All reported holdings are shown as direct beneficial ownership.
On 24 July 2025, West Pharmaceutical Services, Inc. (NYSE: WST) filed a Form 8-K disclosing that it has furnished (not filed) its second-quarter 2025 results under Item 2.02 and Item 7.01. The company attached two exhibits:
- 99.1 鈥� press release announcing Q2 2025 financial results
- 99.2 鈥� investor presentation used on the accompanying conference call
West Pharmaceutical Services, Inc. (WST) 鈥� Form 4 insider filing
On 30 June 2025, director Janet Brutschea Haugen reported an equity-based compensation transaction:
- 58 Phantom Stock Units (deferred share equivalents) were acquired (Code A) at an indicated reference price of $218.80 per unit.
- Following the award, Haugen now holds 114.06 phantom units and 1,318.4 common shares, all in direct ownership.
Phantom units convert to common stock only after the director leaves the board, indicating a long-term alignment of interests rather than an immediate open-market purchase or sale. No common-stock transactions were reported, and the filing does not reference any Rule 10b5-1 trading plan.
FAQ
What is the current stock price of West Pharm Svcs (WST)?
What is the market cap of West Pharm Svcs (WST)?
